Коронавирус и другие пандемии.
7,005,416
32,281
|
DeC ( Профессионал ) |
| 03 ноя 2021 15:14:05 |
Eli Lilly
новая дискуссия Дискуссия 87
Eli Lilly отозвала в Европе заявку на рассмотрение ее комбинированного терапии от ковида препаратами bamlanivimab и etesevimab
компания ссылается на низкий спрос на терапию в Европе
Eli Lilly has withdrawn from a real-time review conducted by the EMA for bamlanivimab and etesevimab, a combination of monoclonal antibodies developed by the company for COVID-19. Lilly has cited the lack of demand for the therapy in EU countries for its decision
компания ссылается на низкий спрос на терапию в Европе
Eli Lilly has withdrawn from a real-time review conducted by the EMA for bamlanivimab and etesevimab, a combination of monoclonal antibodies developed by the company for COVID-19. Lilly has cited the lack of demand for the therapy in EU countries for its decision
ОТВЕТЫ (0)
Комментарии не найдены!